Figure 2.
α-TAT1 undergoes Exp1 mediated nuclear export. (a–l) (a) Coimmunoprecipitation of endogenous Exp1 with GFP-α-TAT1 (molecular weights in kD are indicated); (b) intracellular distribution of mVenus-α-TAT1 with vehicle (EtOH) and 100 nM LMB treatment; nuclei are indicated in red dotted lines; (c) categorical analysis (WT: 263, vehicle: 300, LMB: 255 cells); (d) ratiometric analysis (WT: 125, vehicle: 116, LMB: 163 cells) and (e) colocalization analysis (WT: 55, vehicle: 54, LMB: 52 cells) of mVenus-α-TAT1 localization with vehicle and LMB treatment; (f) immunofluorescence images showing acetylated and total α-tubulin in HeLa cells with vehicle or LMB treatment; (g) ratio of acetylated to total α-tubulin with vehicle or LMB treatment (vehicle:120, LMB: 130 cells); (h) changes in intracellular localization of mVenus-α-TAT1 on LMB treatment; (i) changes in nuclear intensity of mVenus-α-TAT1 on LMB treatment (black line shows the mean and gray line indicate the 95% confidence interval; n = 26); (j) categorical analysis (vehicle: 274, LMB 1 nM: 329, LMB 10 nM: 291, LMB 100 nM: 295 cells) and (k) ratiometric analysis of mVenus-α-TAT1 localization on vehicle (103) or LMB treatment (1 nM: 121, 10 nM: 122 and 100 nM: 103 cells); (l) immunostaining with anti–α-TAT1 antibody showing intracellular localization of endogenous α-TAT1 in MEF cells on treatment with vehicle (EtOH) or 100 nM LMB; red dotted lines outline nuclei as identified by DAPI. Scale bar = 10 µm. ***, P < 0.001 or as shown, Student’s t test. For categorical analyses, Nuc: Nucleus enriched, Diff: Diffused, Cyto: Cytosolic. Source data are available for this figure: SourceData F2.

α-TAT1 undergoes Exp1 mediated nuclear export. (a–l) (a) Coimmunoprecipitation of endogenous Exp1 with GFP-α-TAT1 (molecular weights in kD are indicated); (b) intracellular distribution of mVenus-α-TAT1 with vehicle (EtOH) and 100 nM LMB treatment; nuclei are indicated in red dotted lines; (c) categorical analysis (WT: 263, vehicle: 300, LMB: 255 cells); (d) ratiometric analysis (WT: 125, vehicle: 116, LMB: 163 cells) and (e) colocalization analysis (WT: 55, vehicle: 54, LMB: 52 cells) of mVenus-α-TAT1 localization with vehicle and LMB treatment; (f) immunofluorescence images showing acetylated and total α-tubulin in HeLa cells with vehicle or LMB treatment; (g) ratio of acetylated to total α-tubulin with vehicle or LMB treatment (vehicle:120, LMB: 130 cells); (h) changes in intracellular localization of mVenus-α-TAT1 on LMB treatment; (i) changes in nuclear intensity of mVenus-α-TAT1 on LMB treatment (black line shows the mean and gray line indicate the 95% confidence interval; n = 26); (j) categorical analysis (vehicle: 274, LMB 1 nM: 329, LMB 10 nM: 291, LMB 100 nM: 295 cells) and (k) ratiometric analysis of mVenus-α-TAT1 localization on vehicle (103) or LMB treatment (1 nM: 121, 10 nM: 122 and 100 nM: 103 cells); (l) immunostaining with anti–α-TAT1 antibody showing intracellular localization of endogenous α-TAT1 in MEF cells on treatment with vehicle (EtOH) or 100 nM LMB; red dotted lines outline nuclei as identified by DAPI. Scale bar = 10 µm. ***, P < 0.001 or as shown, Student’s t test. For categorical analyses, Nuc: Nucleus enriched, Diff: Diffused, Cyto: Cytosolic. Source data are available for this figure: SourceData F2.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal